BIOFARM S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.826 RON | +0.49% |
|
0.00% | +0.24% |
| 2023 | Biofarm S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
| 2023 | Biofarm S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2021 | 239M 51.54M | Sales 2022 | 277M 59.72M | Capitalization | 607M 131M |
|---|---|---|---|---|---|
| Net income 2021 | 60M 12.94M | Net income 2022 | 70M 15.09M | EV / Sales 2021 | 3 x |
| Net cash position 2021 | 104M 22.39M | Net cash position 2022 | 82.71M 17.83M | EV / Sales 2022 | 1.89 x |
| P/E ratio 2021 |
14.7
x | P/E ratio 2022 |
9.31
x | Employees | 402 |
| Yield 2021 |
2.88% | Yield 2022 |
4.87% | Free-Float | 11.67% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.49% | ||
| Current month | +0.24% | ||
| 1 month | +1.72% | ||
| 3 months | -6.77% | ||
| 6 months | +5.63% | ||
| Current year | +0.24% |
1 week
0.81
0.83
1 month
0.810.83
Current year
0.800.91
1 year
0.610.91
3 years
0.530.91
5 years
0.310.91
10 years
0.210.91
| Managers | Title | Age | Since |
|---|---|---|---|
Catalin Vicol
CEO | Chief Executive Officer | 49 | 18-11-14 |
Mihai Zoescu
DFI | Director of Finance/CFO | 44 | 21-01-17 |
Lucian Bogaciu
ADM | Chief Administrative Officer | 50 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Catalin Vicol
CEO | Chief Executive Officer | 49 | 18-11-14 |
| Director/Board Member | 43 | 15-12-09 | |
| Director/Board Member | 49 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 0.826 | +0.49% | 38,337 |
| 24-04-24 | 0.822 | +0.24% | 17,030 |
| 24-04-23 | 0.82 | -1.20% | 44,580 |
| 24-04-22 | 0.83 | +0.24% | 38,890 |
| 24-04-19 | 0.828 | +0.24% | 42,368 |
End-of-day quote Bucharest S.E., April 24, 2024
More quotes
Biofarm SA is a Romania-based company engaged in the pharmaceutical sector. The Company focuses on the production and marketing of pharmaceutical preparations. The Company is active in the manufacture and wholesale of over the counter drugs, prescription medications and dietary supplements. The Companyâs product portfolio includes pharmaceutical preparations for digestive system, musculoskeletal system, immune stimulation, respiratory system, cold and flu symptoms and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants and cosmetics, among others. Additionally, the Company offers services, such as consultancy on Romanian pharmaceutical market, manufacturing of non-sterile products, the investment in research, promotion and packaging. The main shareholder of the Company is Societatea de Investitii Financiare Muntenia SA.
Sector
Pharmaceuticals
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +0.24% | 174M | |
| +19.87% | 22.25B | |
| +13.49% | 14.39B | |
| +13.38% | 13.55B | |
| +38.75% | 11.27B | |
| -9.00% | 6.95B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.35% | 5.01B | |
| -5.36% | 4.51B |
- Stock Market
- Equities
- BIO Stock
